Expertise in
8
conditions

Francesco Panzuto

1035 Grottarossa Street, 
Rome, IT 
Expertise in
8
conditions
1035 Grottarossa Street, 
Rome, IT 

Overview

Francesco Panzuto practices practicing medicine in Rome, Italy.

Mr. Panzuto is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreatic Cancer, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

He is actively involved in clinical research, co-authoring 147 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

1035 Grottarossa Street, Rome, 00189, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
Enrollment Status: Completed
Publish Date: April 28, 2026
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drugs: Lutathera, Octreotide
Study Phase: Phase 3
View 1 Less Clinical Trial

147 Total Publications

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).
Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).
Journal: BMC cancer
Published: June 13, 2026

Frequently Asked Questions about Francesco Panzuto

Is Francesco Panzuto a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Francesco Panzuto is classified as an Elite expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Francesco Panzuto participate in research or clinical trials?

Yes. Francesco Panzuto has published 147 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Francesco Panzuto's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Panzuto's expertise for a condition
ConditionClose
View All 29 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile